PHASTAR

Executive Summary

PHASTAR is a global biometrics contract research organization (CRO) founded in 2007, headquartered in London, specializing in biostatistics, data management, and data science for clinical trials. The company supports pharmaceutical, biotechnology, and medical device clients by transforming complex clinical data into actionable insights, thereby accelerating regulatory submissions and drug approvals. With a focus on high-quality statistical analysis and data integrity, PHASTAR has positioned itself as a trusted partner in the increasingly data-driven clinical research landscape. Its expertise in biostatistics and data management enables it to capture growing demand for specialized CRO services, particularly as the industry emphasizes efficiency and rapid decision-making. As the clinical trial market expands, driven by complex therapeutic areas and precision medicine, PHASTAR's niche in biometrics offers a competitive advantage. The company benefits from the trend of pharmaceutical companies outsourcing biostatistics functions to specialized providers. While privately held and lacking public financial disclosures, PHASTAR likely generates steady revenue from repeat business and new client acquisitions. Potential growth catalysts include major contract wins, geographic expansion, or adoption of advanced analytics platforms. However, competition from larger CROs and reliance on a limited number of key clients pose risks. Overall, PHASTAR appears well-positioned in its niche, though limited public information constrains conviction.

Upcoming Catalysts (preview)

• Q3 2026Secures major contract with top-10 pharma company30% success
• H2 2026Expands into oncology or rare disease biostatistics services40% success